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Abstract 
 
Aims: to determine whether anticoagulation therapy in the treatment of neonatal cerebral 
sinovenous thrombosis (CSVT) improves outcomes, in the presence or absence of pre-
existing intracerebral haemorrhage (ICH). 
Methods: We searched CENTRAL; MEDLINE; Embase; CINAHL and the Web of Science, and 
clinical trial databases. We considered data from both retrospective and prospective cohort 
studies, case series, and randomised controlled studies evaluating outcomes of CSVT treated 
with anticoagulation or no anticoagulation. 
Studies were included if they involved infants either less than 28 days of age, or less than 44 
weeks post-menstrual age at time of diagnosis of CSVT in which anticoagulation was 
considered.  
Results: Seven non-randomised studies were included in meta-analysis. Anticoagulation 
therapy had no significant effect on mortality prior to discharge either in the presence or 
absence of pre-existing ICH, nor on the incidence of extension of pre-existing ICH. 
Anticoagulation therapy was associated with a reduced risk of propagation of thrombus (RR 
0.14 95%CI 0.03-0.72). 
Interpretation: There are no randomised trials assessing the safety and efficacy of 
anticoagulation therapy in the treatment of neonatal CSVT. The results of this meta-analysis 
would justify a position of equipoise and support the need for well designed randomised 
controlled trials of anti-coagulation therapy in this population. 
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Short form title:   Anticoagulation in neonatal cerebral sinovenous thrombosis 
What this paper adds: 
 There are no randomised controlled studies evaluating the use anticoagulation 
therapy in neonatal CSVT 
 Anticoagulation therapy may reduce thrombus propagation  
 No evidence of increased morbidity or mortality with anticoagulation therapy was 
demonstrated 
 A position of equipoise is justified, supporting the need for placebo controlled 
randomised trials 
 
Funding and support 
No funding or support was received for the undertaking of this systematic review and meta-
analysis 
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Introduction 
Cerebral sino venous thrombosis (CSVT) has a peak incidence in the neonatal period, with an 
incidence estimated between 2 and 12 per 100,000 live newborns.(1, 2) It is associated with 
significant morbidity, including visual deficits,(2) seizures,(2) sensorimotor impairments (3)  
and mortality.(2) The clinical presentations of neonatal CSVT are varied. Although seizures 
are the most frequently reported presenting feature, lethargy or reduced consciousness, 
apnoea, hyper or hypotonia, focal motor deficits and respiratory distress have all been 
reported.(2-5) CSVT may also be detected in asymptomatic infants imaged for unrelated 
reasons. (2, 4) Pathogenesis is multifactorial and includes various maternal and neonatal 
factors, as well as prothrombotic coagulant factors.  
 
CSVT also occurs in adults and children, where the mainstay of treatment is anticoagulation 
with unfractionated or low-molecular-weight heparin to increase the rate of resolution, and 
prevent the propagation of thrombus. This may reduce the extent of thrombus related 
venous infarct, and haemorrhagic transformation. This treatment is supported by a 
reasonable evidence base in the adult population (6) and there is some evidence for its use 
in the pediatric population.(7) Nonetheless, there remains extensive variation in practice in 
both populations.(8, 9) 
 
There is ongoing uncertainty over the use of anticoagulation in neonatal CSVT. It may be 
considered to be an entity discreet from pediatric and adult CSVT both due to the unique 
but transient risk factors present in the neonatal period and the particular fragility of the 
neonatal brain.(10) Furthermore, this population has a high incidence of pre-existing 
intracerebral haemorrhage (ICH) at the time of diagnosis. Treatment with anticoagulation 
therapy could then carry a potential risk of extending existing haemorrhage resulting in 
poorer outcomes. 
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The use of anticoagulation therapy in the management of neonatal CSVT has been included 
in several guidelines (7, 11) yet its use in infants with pre-existing ICH remains contentious. 
Few studies have attempted to assess the safety and efficacy of anticoagulation therapy in 
neonatal CSVT, and crucially, the evidence for ACT has not been considered in infants with 
pre-existing ICH where treatment decisions may be the most challenging.  
 
In this systematic review we assess the evidence for anticoagulation therapy in the 
treatment of neonatal CSVT both in the presence and absence of pre-existing ICH. Our 
objective was to test the hypothesis that anticoagulation therapy in the treatment of CSVT 
improves mortality rate and long-term neurological outcome in neonates. We further 
hypothesised that treatment is also beneficial in infants with pre-existing ICH, despite a 
theoretical increased risk of extension of haemorrhage.  
Objectives 
To determine whether anticoagulation therapy in the treatment of cerebral sinovenous 
thrombosis in neonates (less than 28 days age, or less than 44 weeks post-menstrual age at 
presentation and with or without pre-existing ICH) is associated with lower mortality prior to 
discharge, reduced risk of extension of pre-existing haemorrhage, reduced rates of 
thrombus propagation and improved neurodevelopmental outcomes at two years of age.  
  
Methods   
No protocol was published in advance of this systematic review and meta-analysis. 
Search methods for identification of studies   
Electronic searches   
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane 
Library); MEDLINE via Ovid SP (January 1966 to 1st October 2017); EMBASE vias Ovid SP 
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(January 1980 to 1st October 2017); CINAHL via EBSCO Host (1982 to 1st October 2017) and 
Web of Science (1985 to 1st October 2017). We used the Cochrane highly sensitive search 
strategy for identifying randomised controlled trials as suggested in the Cochrane Handbook 
for Systematic Reviews of Interventions (Higgins 2011). MeSH headings were used when 
available  as shown in Table 1. An additional free text search was conducted for each search 
engine using: "Newborn" AND  (" Cerebral venous" OR "cerebral sinovenous") AND 
("thrombus" OR "thrombosis") 
In addition we searched the following registries:  http://www.controlled-trials.com; 
http://clinicaltrials.gov; http://www.anzctr.org.au  
We also checked the reference lists of all identified studies for further relevant studies. 
Conference abstracts were not included in the systematic review, but were used to identify 
published papers. 
 
Data collection and analysis   
Selection of studies, data extraction and management   
After identifying studies using the electronic databases, the bibliographies were reviewed to 
identify additional relevant studies, and a full text second stage screening was performed by 
2 reviewers (TR, RS). Initial records were screened for relevance, and the abstracts of those 
records of potential relevance were reviewed. Studies that potentially fulfilled inclusion 
criteria based on the abstract were reviewed as full text. A decision was made as to eligibility 
for inclusion, and any disagreement between reviewers was resolved by discussion. 
A standardised data extraction form was used by both reviewers.(12) 
Another reviewer (TA) assessed the quality of studies independently and any differences 
were reconciled by mutual agreement. 
The details of all excluded studies are listed with reason for exclusion in Table 2.  
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Inclusion criteria 
We considered data from both retrospective and prospective cohort studies, case series, 
randomised controlled studies evaluating outcomes of CSVT treated with anticoagulation or 
no anticoagulation. 
Studies were included if they involved infants either less than 28 days of age, or less than 44 
weeks post-menstrual age at time of diagnosis of CSVT in which anticoagulation was 
considered in the presence or absence of intracranial haemorrhage.  
Primary outcomes considered were death or neurological sequelae at 2 years follow-up and 
death prior to discharge from hospital. 
Secondary outcomes considered were extension of thrombus, and extension of intracranial 
haemorrhage. 
 
Characteristics of included studies are summarised in Table 3. 
 
Assessment of risk of bias in included studies   
Risk of bias was independently assessed by two reviewers (TR,RS) using the Cochrane 
Collaboration's domain based tool for assessing risk of bias. Selection bias, performance 
bias, detection bias, attrition bias, reporting bias and other bias were scored. An overall risk 
of bias for each study was 'high risk of bias', 'low risk of bias' or 'unclear risk of bias'. This was 
made according to guidance in the Cochrane Handbook for Systematic Reviews of 
Interventions(13). Any disagreements were resolved by consensus, or where necessary, 
discussion with TA.  
 
Measures of treatment effect   
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Categorical data were extracted for each intervention group and the risk ratio (RR) and risk 
difference (RD) calculated. If the risk difference was statistically significant the number 
needed to treat or harm was calculated.  
 
Assessment of heterogeneity   
Heterogeneity was quantified with the I2 statistic calculated as described in the Cochrane 
Handbook for Systematic Reviews of Interventions.(13) The thresholds for interpreting I2 
are: 
· 0% to 40%: may represent insignificant heterogeneity 
· 30-60%: may represent moderate heterogeneity 
· 50-90%: may represent substantial heterogeneity 
· >75%: may represent considerable heterogeneity 
 
Were I2 to exceed 75% we would have conducted a sensitivity analysis to explain the source 
of heterogeneity. 
 
Assessment of reporting biases   
Where meta-analysis was undertaken a funnel plot was used to assess publication bias. 
 
Data synthesis   
Meta-analysis was performed using RevMan using a fixed-effect model where there were 
two or more studies with comparable populations and treatment interventions. 
We present our results with 95% CIs. We assessed RRs and RDs. The outcomes of 
comparable trials were analysed with 95% CIs to estimate treatment effect. If appropriate, 
we compared results using forest plots with the RR as the point estimate for dichotomous 
outcomes.  
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Results: 
Figure 1. 
Seven studies presented outcomes from neonatal CSVT with sufficient detail to be included 
in meta-analysis  and are shown in Table 3. Authors assessment of bias is presented in Figure 
2. Fitzgerald et al. performed a single center retrospective review of 42 patients with 
neonatal CSVT, of whom 25 had pre-existing ICH. Three without ICH received 
anticoagulation.(4) Gentilomo et al. conducted a single center retrospective review 
identifying five neonates with CSVT of whom two received anticoagulation therapy.(14) 
Kenet et al. identified eight cases of neonatal CSVT in a multicenter case control study, four 
of which received anticoagulation therapy.(15) Kersbergen et al. identified ten cases of 
neonatal CSVT in a single center of whom seven received anticoagulation therapy.(16) 
Moharir et al. published two retrospective analyses of cases of neonatal CSVT that were 
prospectively enrolled into a study.  
In the first study containing 83 cases of neonatal CSVT, 59 neonates had ICH at presentation 
of whom 21 received anticoagulation therapy.  Of the remaining 24 without ICH at 
presentation, 17 received anticoagulation therapy.(17)  
In the latter study, 71 of 104 neonates had ICH at presentation, of whom 29 received 
anticoagulation therapy. Of the remaining 33 without ICH at presentation, 24 received 
anticoagulation therapy.(3)  The data from patients in the earlier study were included in the 
later study. Incomplete reporting of outcome variables required inclusion of the earlier 
study where data were not presented in the larger study. (3) Pergami et al. conducted a 
retrospective review of neonatal CSVT identifying 22 cases of whom five received 
anticoagulation therapy without complication.(18) 
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In none of the studies was treatment allocated by randomization. Decision to treat was 
based in all cases on local protocols, and individual clinicians assessment of the likelihood of 
benefit. This would be a significant source of bias in the results of all the included studies.  
Sufficient data were reported to meta-analyse the effect of anticoagulation therapy on 
mortality prior to discharge in neonates with pre-existing ICH and without. (Figures 3 to 6) 
In neonates without pre-existing ICH there was no effect of anticoagulant therapy on 
mortality prior to hospital discharge (RR 0.91; 95% CI: 0.23-3.57). There was a non-significant 
trend towards lower mortality prior to hospital discharge in neonates with pre-existing ICH 
who received anticoagulation therapy compared to those who did not (RR 0.14; 95% CI 0.02-
1.21). 
Two studies presented sufficient data to meta-analyse the effect of anticoagulation therapy 
on the incidence of extension of ICH in neonates with pre-existing ICH.(16, 18) This showed a 
non-significant trend towards lower rates of extension of haemorrhage in those that 
received anticoagulant therapy (RR 0.35; 95% CI: 0.05-2.34). (Figures 7 & 8) 
A meta-analysis of two studies demonstrated a lower risk of propagation of thrombus in 
neonates that received anti-coagulation therapy compared to those that did not 
(irrespective of ICH status) (RR 0.09; 95% CI: 0.02-0.47). (Figure 9 & 10) 
While several studies reported neurodevelopmental outcomes (2-4, 14, 16, 17, 19) in all 
cases the time point and variable tools for assessment precluded comparison. In one study 
predictors of poor neurological outcome at last follow-up were examined. Not receiving 
anticoagulation therapy was a predictor of poorer neurodevelopmental outcome on 
univariate but not multivariate analysis.(17) 
No meta-analysis of outcome data was possible.  
 
 
Discussion 
  11 
In this meta-analysis in hospital mortality did not differ significantly between those who 
received anticoagulation therapy and those that did not. However, there was a trend 
towards lower mortality in those infants with pre-existing ICH receiving anticoagulation 
therapy. 
Our meta-analysis suggests a significantly reduced risk of thrombus propagation in neonates 
with CSVT who receive anticoagulation therapy. There was no greater risk of new or 
extension of haemorrhage in those infants with pre-existing ICH who received 
anticoagulation therapy compared to those who did not.  
 
While there is reasonable evidence for the use of anticoagulation in CSVT in adults (20) and 
some evidence for safety and efficacy in children, (7) there is limited data to guide usage of 
anticoagulation therapy in neonates with CSVT. Nonetheless there are expert consensus 
guidelines which provide varied degrees of support for the use of anticoagulation in 
neonates.(11, 21, 22) Although we identified several studies which reported the use of 
anticoagulation therapy for CSVT in the neonatal population, they were limited to 
retrospective reviews of cases.(2, 4, 5, 14-16, 23, 24) Of interest, none of these studies 
reported a significantly higher rate of intracranial haemorrhage in neonates that received 
anticoagulation therapy. In contrast, in the largest prospective study identified, Moharir et 
al. reported a slightly higher but non-significant rate of major ICH in 6% of anticoagulated 
neonates compared to 3% of untreated neonates (p=0.536).(17) Our meta-analysis of the 
few studies which reported outcomes according to both the presence of pre-existing ICH 
and anticoagulation therapy suggested that the risk of extension in infants with pre-existing 
ICH is not increased by anticoagulation therapy.   
 
In this meta-analysis the risk of death prior to discharge was not higher in infants who 
received anticoagulation therapy compared to controls either in the presence or absence of 
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pre-existing ICH. In the presence of ICH there was a trend towards lower mortality in those 
that received anticoagulation therapy. However, as the use of anticoagulation would have 
been based on clinician assessment (and perceived stability) of individual infants, there is 
high risk of selection bias and these results must be interpreted with caution. 
 
This meta-analysis demonstrated a significant benefit of anticoagulation therapy in reducing 
the risk of thrombus propagation. Propagation of thrombus has been associated with an 
increased rate of subsequent venous infarction.(3) 
Of note, many of the included neonates were initiated on anticoagulation therapy only 
following demonstrated propagation of thrombus after diagnosis and an initial clinical 
decision not to treat, with associated close monitoring with imaging. Those that were not 
commenced on anticoagulation therapy were monitored for propagation with MRV, 
whereas those treated were more likely to be imaged using CT to assess for anticoagulation 
therapy related haemorrhage.(3) The reduced sensitivity of CT in detecting thrombus would 
make a degree of detection bias highly likely, with those reimaged with MRV more likely to 
have extension detected.  
 
There is a reasonable explanation for the benefit of anticoagulation, as haemorrhage in the 
context of neonatal CSVT is most likely to arise from venous infarction due to raised venous 
pressure. While the risk of bias is high in these studies, there appears to be some support for 
a benefit of anticoagulation therapy in reducing thrombus propagation. This may plausibly 
decrease venous pressures and therefore reduce both further parenchymal damage through 
venous infarction and the risk of haemorrhagic transformation. 
The studies included in this review comprised a heterogeneous population. 
Numerous risk factors for CSVT and ICH vary between the term and preterm population. The 
studies included in this systematic review included both term and prematurely born infants, 
  13 
however none of the studies presented data in such a way that these two groups could be 
analysed separately. This is an important consideration for future studies, as the risks and 
benefits of anticoagulation therapy may differ between these two populations.  
Furthermore, studies addressed the varying underlying causes of CSVT differently. Pergami 
et al. excluded infants with CSVT secondary to CNS infection which were included in other 
studies. Short and long term outcomes may be heavily influence by the precipitating 
condition yet it was not possible to explore this with the studies currently available.  
 
Across the studies there is variation in the anticoagulation therapy used; in the timing of 
anticoagulation therapy (which in some cases was delayed until thrombus propagation was 
demonstrated); in the agents used; the dosing regime and duration of treatment. While 
treatment regimes have been proposed (7) these are based on expert opinion. As most of 
the published studies in the treatment of neonatal CSVT are retrospective, this has not been 
formally evaluated. 
 
The meta-analysis has been performed on a small number of small, non-randomised studies 
and therefore caution must be exercised in interpreting the results.(25) Nonetheless, it has 
allowed a comparison of studies to be undertaken and demonstrated some consistency in 
findings, which may inform future research design.(26) 
 
Conclusion 
Treatment with anticoagulation therapy is variably employed in the management of 
neonatal CSVT, but there remains insufficient data to assess its safety and efficacy.  
While the results of this meta-analysis provide some support for the use of anticoagulation 
therapy in this population, the studies included are at high risk of bias, and caution must be 
exercised in their interpretation.  However, the results of this meta-analysis would justify a 
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position of equipoise and support the need for well designed randomised controlled trials of 
anti-coagulation therapy in this population. 
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Resource Search terms 
Cochrane central register of controlled trials (infant, newborn[MeSH Terms]) AND (Sinus thrombosis, intracranial[MeSH Terms]) 
MEDLINE (infant, newborn[MeSH Terms]) AND ((Cerebral thrombosis[MeSH Terms]) OR (Cranial sinus thrombosis[MeSH Terms]))  
EMBASE Newborn AND cerebral thrombosis (including related terms) 
CINAHL via EBSCO (MH "Infant, Newborn+") AND ((MH "Intracranial Thrombosis+") OR (MH "Sinus Thrombosis, Intracranial+"))  
Web of Science TOPIC(infant, newborn) AND TOPIC (cerebral venous sinus thrombosis) 
www.controlled-trials.com  Text search: "Newborn" AND  (" Cerebral venous" OR "cerebral sinovenous") AND ("thrombus" OR "thrombosis") 
clinicaltrials.gov Text search: "Newborn" AND  (" Cerebral venous" OR "cerebral sinovenous") AND ("thrombus" OR "thrombosis") 
www.anzctr.org.au Text search: "Newborn" AND  (" Cerebral venous" OR "cerebral sinovenous") AND ("thrombus" OR "thrombosis") 
Table 1: Search terms employed, by search engine 
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Study Reason for exclusion 
Berfelo  2010 (2) Study included 52 neonates, 43 with pre-existing ICH. Now outcomes were 
presented with sufficient detail for meta-analysis 
DeVeber 1998(27) Study included 8 neonates however no outcome data could be extracted as 
presented as part of a larger paediatric study 
DeVeber 2001(28) Study included 69 neonates with CSVT, however no outcome data could be 
extracted for relevant groups (neonates receiving or not receiving ACT) 
Grunt 2010(29) 21 neonates with CSVT. Insufficient data presented to include in meta-analysis 
Jordan 2010(5) 84 neonates with CSVT, 43 of whom received antithrombotic medication. No 
data for specified outcome measures could be extracted. 
Kenet 2007(19) 75 neonates with CSVT. Unable to extract data for specified outcome measures 
depending on administration of ACT. 
Steinlin 2005(30) 17 CSVT in paediatric population. Unable to extract neonatal data for specified 
outcome measures 
Tuckuviene 2011(23) 7 Neonates included. Unable to extract data for specified outcome measures 
Vieira 2010(24) Possibly 6 neonates included, though varying use of terminology. Not possible 
to extract data for specified outcome measures. 
Wasay 2008(31) 25 neonates included. Not possible to extract data for specified outcome 
measures 
Table 2: Characteristics of excluded studies 
 
  
  20 
 
  Methods Participants Interventions Outcomes 
Fitzgerald 2006 
Retrospective 
single centre 
study 
42 neonates, six were “premature”.  25 with pre-
existing IVH 
3 received ACT with heparin.  Non-randomised: 
treatment at clinicians discretion 
Cognitive or motor impairment, epilepsy at last follow-
up, in hospital death 
Gentilomo 2008 
Retrospective 
single centre 
study 
5 neonates, gestation uncertain. Presented on 
median day 4 of life (range 1-6). 
2 received ACT with LMWH.  Non-randomised: 
treatment at clinicians discretion 
In hospital mortality. Neurological sequelae at last clinic  
Kenet 2004 
Multicentre 
case control 
8 neonates, none born prematurely (gestation or 
age at presentation not given) 
4 received ACT with LMWH.  Non-randomised: 
treatment at clinicians discretion 
Death, neurological sequelae 
Kersbergen 
2009 
Retrospective 
single centre 
study 
10 neonates with CSVT and unilateral thalamic 
haemorrhage. 32-42 weeks gestation. Presented at 
median day 5 of life (range 0-19 days) 
7 received anticoagulation  therapy with LMWH.  
Non-randomised: treatment at clinicians 
discretion 
Death, recanalization, neurological sequelae 
Moharir 2010 
Retrospective 
single centre 
study  
Neonates and children. 83 Neonates included 
irrespective of gestation  
29 received ACT with LMWH, UFH or Warfarin.  
Non-randomised: treatment at clinicians 
discretion 
ACT-related major haemorrhage, 
propagation,recanalization, and clinical outcome 
(favorable or unfavorable (Neurological sequelae or 
death)). 
Moharir 2011 
Retrospective 
multicentre 
study 
104 Neonates diagnosed with CSVT, irrespective of 
gestation. Gestation of neonates not reported. 
Presented at median 6 days of age (range 0-27) 
53 neonates  received ACT with LMWH or UFH.  
Non-randomised: treatment at clinicians 
discretion 
Death, thrombus propagation, recanalization, 
neurodevelopmental outcome (variable time points of 
assessment) 
Pergami 2011  
Retrospective 
multicentre 
study 
22 Neonates with confirmed CSVT, 6 preterm 
(gestational age 31-35 weeks). Age at presentation 
1-21 days. Infants with CNS infection excluded.  
Rehydration in 18, anticoagulation in 5 with 
LMWH. Non-randomised: treatment at clinicians 
discretion 
Death before discharge, thrombus propagation, new or 
extension of haemorrhage 
Table 3: Characteristics of included studies
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Figure 1: Study flow diagram. 
 
Figure 2: Risk of bias summary: review authors' judgements about risk of bias item for 
each included study. Red (-) demonstrates high risk of bias. Yellow (?) demonstrates 
unclear risk of bias 
 
Figure 3: Effect of anticoagulation on mortality before hospital discharge in neonatal CSVT 
without pre-existing ICH 
 
Figure 4: Funnel plot of studies evaluating the effect of anticoagulation on mortality 
before hospital discharge in neonatal CSVT without pre-existing ICH 
 
Figure 5: Effect of anticoagulation on mortality before hospital discharge in neonatal CSVT 
with pre-existing ICH 
 
Figure 6: Funnel plot of studies evaluating the effect of anticoagulation on mortality 
before hospital discharge in neonatal CSVT with pre-existing ICH 
 
Figure 7: Effect of anticoagulation on incidence of extension of ICH in neonatal CSVT with 
pre-existing ICH 
 
Figure 8: Funnel plot of studies evaluating the effect of anticoagulation on incidence of 
extension of ICH in neonatal CSVT with pre-existing ICH 
 
Figure 9: Effect of anticoagulation on risk of propagation of thrombus 
 
Figure 10: Funnel plot of studies evaluating the effect of anticoagulation on risk of 
propagation of thrombus 
 
 
 
 
